169 related articles for article (PubMed ID: 25560410)
1. Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in mice.
Manning ML; Mason-Osann E; Onda M; Pastan I
J Immunol; 2015 Feb; 194(4):1695-701. PubMed ID: 25560410
[TBL] [Abstract][Full Text] [Related]
2. Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin.
King EM; Mazor R; Çuburu N; Pastan I
J Immunol; 2018 Mar; 200(6):2038-2045. PubMed ID: 29431691
[TBL] [Abstract][Full Text] [Related]
3. Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.
Mossoba ME; Onda M; Taylor J; Massey PR; Treadwell S; Sharon E; Hassan R; Pastan I; Fowler DH
Clin Cancer Res; 2011 Jun; 17(11):3697-705. PubMed ID: 21521777
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
Onda M; Nagata S; FitzGerald DJ; Beers R; Fisher RJ; Vincent JJ; Lee B; Nakamura M; Hwang J; Kreitman RJ; Hassan R; Pastan I
J Immunol; 2006 Dec; 177(12):8822-34. PubMed ID: 17142785
[TBL] [Abstract][Full Text] [Related]
5. Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.
Mazor R; Zhang J; Xiang L; Addissie S; Awuah P; Beers R; Hassan R; Pastan I
Mol Cancer Ther; 2015 Dec; 14(12):2789-96. PubMed ID: 26443804
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of Immunotoxins Containing
Mazor R; Pastan I
Front Immunol; 2020; 11():1261. PubMed ID: 32695104
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of therapeutic recombinant immunotoxins.
Mazor R; Onda M; Pastan I
Immunol Rev; 2016 Mar; 270(1):152-64. PubMed ID: 26864110
[TBL] [Abstract][Full Text] [Related]
8. A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice.
Hansen JK; Weldon JE; Xiang L; Beers R; Onda M; Pastan I
J Immunother; 2010 Apr; 33(3):297-304. PubMed ID: 20445350
[TBL] [Abstract][Full Text] [Related]
9. Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line.
Hollevoet K; Mason-Osann E; Müller F; Pastan I
PLoS One; 2015; 10(3):e0122462. PubMed ID: 25803818
[TBL] [Abstract][Full Text] [Related]
10. Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.
Cerise A; Bera TK; Liu X; Wei J; Pastan I
Clin Colorectal Cancer; 2019 Sep; 18(3):192-199.e1. PubMed ID: 31345777
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice.
Pai LH; FitzGerald DJ; Tepper M; Schacter B; Spitalny G; Pastan I
Cancer Res; 1990 Dec; 50(24):7750-3. PubMed ID: 2253218
[TBL] [Abstract][Full Text] [Related]
12. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.
Mazor R; Eberle JA; Hu X; Vassall AN; Onda M; Beers R; Lee EC; Kreitman RJ; Lee B; Baker D; King C; Hassan R; Benhar I; Pastan I
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8571-6. PubMed ID: 24799704
[TBL] [Abstract][Full Text] [Related]
13. [Production and properties evaluation of monoclonal antibodies against Pseudomonas aeruginosa exotoxin A].
Soldatenkova AV; Iakovleva IV; Gavrilova NV; Mikhaĭlova NA; Sviridova VV
Zh Mikrobiol Epidemiol Immunobiol; 2014; (1):30-5. PubMed ID: 24738291
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of anti-folate receptor beta antibody conjugated with truncated Pseudomonas exotoxin in the targeting of rheumatoid arthritis synovial macrophages.
Nagayoshi R; Nagai T; Matsushita K; Sato K; Sunahara N; Matsuda T; Nakamura T; Komiya S; Onda M; Matsuyama T
Arthritis Rheum; 2005 Sep; 52(9):2666-75. PubMed ID: 16142741
[TBL] [Abstract][Full Text] [Related]
15. The early marginal zone B cell-initiated T-independent type 2 response resists the proteasome inhibitor bortezomib.
Lang VR; Mielenz D; Neubert K; Böhm C; Schett G; Jäck HM; Voll RE; Meister S
J Immunol; 2010 Nov; 185(9):5637-47. PubMed ID: 20921528
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition is partially effective in attenuating pre-existing immunity against recombinant adeno-associated viral vectors.
Karman J; Gumlaw NK; Zhang J; Jiang JL; Cheng SH; Zhu Y
PLoS One; 2012; 7(4):e34684. PubMed ID: 22514654
[TBL] [Abstract][Full Text] [Related]
17. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.
Onda M; Beers R; Xiang L; Nagata S; Wang QC; Pastan I
Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11311-6. PubMed ID: 18678888
[TBL] [Abstract][Full Text] [Related]
18. Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A.
Kaplan G; Lee F; Onda M; Kolyvas E; Bhardwaj G; Baker D; Pastan I
Toxins (Basel); 2016 Jul; 8(8):. PubMed ID: 27463727
[TBL] [Abstract][Full Text] [Related]
19. Improving the
Kaplan G; Mazor R; Lee F; Jang Y; Leshem Y; Pastan I
Mol Cancer Ther; 2018 Jul; 17(7):1486-1493. PubMed ID: 29695631
[TBL] [Abstract][Full Text] [Related]
20. Preparation of recombinant atoxic form of exotoxin A from Pseudomonas aeruginosa.
Kaloshin AA; Isakov MA; Mikhailova NA; Vertiev JV
Bull Exp Biol Med; 2013 Jan; 154(3):346-50. PubMed ID: 23484197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
